Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1806 | AZD-6482 | 1 | 72 | 0.001 | 11446.8 | 11709.8 | 1742.8 | -3.0 | 0.984 | 0.978 | 2.748 | HCC1806 AZD6482 0 1 72 |
| HCC1806 | AZD-6482 | 1 | 72 | 0.0032 | 11393.8 | 11709.8 | 1742.8 | -2.49 | 0.980 | 0.973 | 2.748 | HCC1806 AZD6482 0 1 72 |
| HCC1806 | AZD-6482 | 3 | 72 | 0.001 | 11446.8 | 11709.8 | 1273.3 | -3.0 | 0.986 | 0.978 | 3.201 | HCC1806 AZD6482 0 3 72 |
| HCC1806 | AZD-6482 | 1 | 72 | 0.032 | 11940.3 | 11709.8 | 1742.8 | -1.49 | 1.010 | 1.020 | 2.748 | HCC1806 AZD6482 0 1 72 |
| HCC1806 | AZD-6482 | 1 | 72 | 0.1 | 12053.8 | 11709.8 | 1742.8 | -1.0 | 1.020 | 1.030 | 2.748 | HCC1806 AZD6482 0 1 72 |
| HCC1806 | AZD-6482 | 1 | 72 | 0.32 | 11558.3 | 11709.8 | 1742.8 | -0.495 | 0.991 | 0.987 | 2.748 | HCC1806 AZD6482 0 1 72 |
| HCC1806 | AZD-6482 | 1 | 72 | 1.0 | 11781.3 | 11709.8 | 1742.8 | 0.0 | 1.000 | 1.010 | 2.748 | HCC1806 AZD6482 0 1 72 |
| HCC1806 | AZD-6482 | 1 | 72 | 3.2 | 11967.3 | 11709.8 | 1742.8 | 0.505 | 1.020 | 1.020 | 2.748 | HCC1806 AZD6482 0 1 72 |
| HCC1806 | AZD-6482 | 2 | 72 | 0.001 | 11446.8 | 11709.8 | 1643.3 | -3.0 | 0.984 | 0.978 | 2.833 | HCC1806 AZD6482 0 2 72 |
| HCC1806 | AZD-6482 | 2 | 72 | 0.0032 | 11393.8 | 11709.8 | 1643.3 | -2.49 | 0.981 | 0.973 | 2.833 | HCC1806 AZD6482 0 2 72 |
| HCC1806 | AZD-6482 | 2 | 72 | 0.01 | 11388.3 | 11709.8 | 1643.3 | -2.0 | 0.980 | 0.973 | 2.833 | HCC1806 AZD6482 0 2 72 |
| HCC1806 | AZD-6482 | 2 | 72 | 0.032 | 11940.3 | 11709.8 | 1643.3 | -1.49 | 1.010 | 1.020 | 2.833 | HCC1806 AZD6482 0 2 72 |
| HCC1806 | AZD-6482 | 2 | 72 | 0.1 | 12053.8 | 11709.8 | 1643.3 | -1.0 | 1.020 | 1.030 | 2.833 | HCC1806 AZD6482 0 2 72 |
| HCC1806 | AZD-6482 | 2 | 72 | 0.32 | 11558.3 | 11709.8 | 1643.3 | -0.495 | 0.991 | 0.987 | 2.833 | HCC1806 AZD6482 0 2 72 |
| HCC1806 | AZD-6482 | 2 | 72 | 1.0 | 11781.3 | 11709.8 | 1643.3 | 0.0 | 1.000 | 1.010 | 2.833 | HCC1806 AZD6482 0 2 72 |
| HCC1806 | AZD-6482 | 2 | 72 | 3.2 | 11967.3 | 11709.8 | 1643.3 | 0.505 | 1.020 | 1.020 | 2.833 | HCC1806 AZD6482 0 2 72 |
| HCC1806 | Trametinib | 3 | 72 | 0.032 | 9495.0 | 11736.5 | 1273.3 | -1.49 | 0.872 | 0.809 | 3.204 | HCC1806 Trametinib 0 3 72 |
| HCC1806 | Trametinib | 3 | 72 | 0.01 | 10202.5 | 11736.5 | 1273.3 | -2.0 | 0.914 | 0.869 | 3.204 | HCC1806 Trametinib 0 3 72 |
| HCC1806 | Trametinib | 2 | 72 | 0.32 | 8807.3 | 11736.5 | 1643.3 | -0.495 | 0.807 | 0.750 | 2.836 | HCC1806 Trametinib 0 2 72 |
| HCC1806 | Trametinib | 2 | 72 | 0.1 | 9344.3 | 11736.5 | 1643.3 | -1.0 | 0.846 | 0.796 | 2.836 | HCC1806 Trametinib 0 2 72 |
| HCC1806 | Trametinib | 2 | 72 | 0.032 | 9495.0 | 11736.5 | 1643.3 | -1.49 | 0.856 | 0.809 | 2.836 | HCC1806 Trametinib 0 2 72 |
| HCC1806 | Trametinib | 2 | 72 | 0.01 | 10202.5 | 11736.5 | 1643.3 | -2.0 | 0.904 | 0.869 | 2.836 | HCC1806 Trametinib 0 2 72 |
| HCC1806 | Trametinib | 1 | 72 | 0.001 | 11633.3 | 11736.5 | 1742.8 | -3.0 | 0.994 | 0.991 | 2.751 | HCC1806 Trametinib 0 1 72 |
| HCC1806 | Trametinib | 1 | 72 | 0.0032 | 10675.8 | 11736.5 | 1742.8 | -2.49 | 0.932 | 0.910 | 2.751 | HCC1806 Trametinib 0 1 72 |
| HCC1806 | Trametinib | 1 | 72 | 0.01 | 10202.5 | 11736.5 | 1742.8 | -2.0 | 0.901 | 0.869 | 2.751 | HCC1806 Trametinib 0 1 72 |